Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

DISCUSSION: In this real-world series of patients, a switch to rFVIII-Fc, based on careful assessment of clinical needs, PK testing and treatment monitoring, was able to optimise individual convenience, efficacy and costs of prophylaxis.
PMID: 31855153 [PubMed - as supplied by publisher]

Source: Blood Transfusion - November 3, 2019 Category: Hematology Authors: Tagliaferri A, Matichecchia A, Rivolta GF, Riccardi F, Quintavalle G, Benegiamo A, Rossi R, Coppola A Tags: Blood Transfus Source Type: research